as of 11-20-2026 3:45pm EST
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | STAMFORD |
| Market Cap: | 2.7B | IPO Year: | 2020 |
| Target Price: | $82.00 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.15 | EPS Growth: | 62.37 |
| 52 Week Low/High: | $32.21 - $170.87 | Next Earning Date: | 11-09-2026 |
| Revenue: | $427,539,000 | Revenue Growth: | 39.97% |
| Revenue Growth (this year): | 11.4% | Revenue Growth (next year): | 19.61% |
| P/E Ratio: | -15.62 | Index: | |
| Free Cash Flow: | 14.3M | FCF Growth: | N/A |
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$84.22
Shares
1,285
Total Value
$108,220.00
Owned After
41,476
SEC Form 4
CHIEF EXECUTIVE OFFICER
Avg Cost/Share
$84.22
Shares
3,692
Total Value
$310,932.12
Owned After
107,227
SEC Form 4
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$83.84
Shares
372
Total Value
$31,188.11
Owned After
41,476
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Feeley Kevin | WGS | CHIEF FINANCIAL OFFICER | Sep 9, 2026 | Sell | $84.22 | 1,285 | $108,220.00 | 41,476 | |
| Stueland Katherine | WGS | CHIEF EXECUTIVE OFFICER | Sep 9, 2026 | Sell | $84.22 | 3,692 | $310,932.12 | 107,227 | |
| Feeley Kevin | WGS | CHIEF FINANCIAL OFFICER | Sep 1, 2026 | Sell | $83.84 | 372 | $31,188.11 | 41,476 |
SEC 8-K filings with transcript text
Nov 9, 2026 · 100% conf.
1D
-9.10%
$60.50
Act: -14.56%
5D
-19.87%
$53.33
20D
-15.83%
$56.01
2 exhibit991-q32026pressrele.htm
Document
Exhibit 99.1
GeneDx Reports Third Quarter 2026 Financial Results
•Reported third quarter 2026 revenue of $123.1 million, including $110.4 million in exome and genome revenue
•Reported exome and genome volume growth of 25% year-over-year with accession growth of 28% year-over-year
•Expanded adjusted gross margin(1) to 72% and adjusted net income(1) to $8.6 million
•Reiterating full year 2026 revenue guidance of $475 to $490 million
•Hosting conference call today at 4:30 p.m. ET
GAITHERSBURG, Md., November 9, 2026 — GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the third quarter of 2026.
“Our Q3 results reflect profitable execution in a growing market, as we translate the rising demand for exome and genome testing into durable revenue growth,” said Katherine Stueland, CEO of GeneDx. “Our priorities are clear: improve the economics of our testing, expand utilization, and deliver leading products at scale. By uniting these priorities with our clinical expertise and differentiated exome and genome capabilities, we are bringing life-changing answers to more families.”
Third Quarter 2026 Financial Results (Unaudited)(1)
Revenue
•Revenue grew to $123.1 million, an increase of 5% year-over-year.
•Exome and genome test revenue grew to $110.4 million, an increase of 12% year-over-year.
Exome and genome volume
•Exome and genome test result volume grew to 32,134, an increase of 25% year-over-year, with accession growth of 28% year-over-year.
Gross margin
•Adjusted gross margin of 72% in the third quarter of 2026 is up from 70% in the second quarter of 2026 and compares to 74% in the third quarter of 2025.
◦GAAP gross margin was 70%.
Operating expenses
•Adjusted total operating expenses were $79.4 million, representing 65% of revenue.
◦Total GAAP operating expenses were $96.5 million.
Net income
•Adjusted net income was $8.6 million, up $8.2 million from the second quarter of 2026 and compared to adjusted net income of $16.1 million in the third quarter of 2025.
◦GAAP net loss was $12.3 million.
Cash position
•Cash, cash equivalents, marketable securities and restricted cash was $171.1 million as of September 30, 2026.
(1)Adjusted gross margin, adjusted total operating expenses and adjusted net income are non-GAAP financial measures. See appendix for a reconciliation of GAAP to non-GAAP figures presented.
GeneDx 2026 Guidance
GeneDx has updated its 2026 guidance and has provided guidance for the fourth quarter of 2026. Management expects GeneDx to deliver:
MetricFull Year 2026 Previous GuidanceFull Year 2026 Updated GuidanceFourth Quarter 2026 Guidance
Revenue $475 to $490 million
$475 to $490 million
$135 million
Exome and genome volume At least 30% growth
At least 28% growth
34,500 tests
Exome and genome revenue At least 20% growth
At least 17% growth
$121 million
Adjusted gross margin Approximately 70%
Approximately 71%
At least 71%
Adjusted net income Positive
Approximately $12 million
Approximately $12 million
Third Quarter 2026 and Recent Business Highlights
Strategic Expansion and Market Leadership
•Announced genome testing portfolio enhancement with long-read whole genome sequencing, reflecting GeneDx's continued focus on genome innovation to expand diagnostic capabilities and deliver more answers to more patients.
•Launched additional customer experience features, including simplified test reports, easy ordering, and report guides to simplify genomic testing from ordering through understanding and communicating results.
•Launched a new online offering designed to expand accessibility of exome testing for pediatric patients with global developmental delay (GDD), intellectual disability (ID) or epilepsy by enabling families to initiate genetic testing online and connect with licensed healthcare providers who can review medical information, order testing, and deliver results without requiring traditional in-person visits.
•Collaborated with Mirum Pharmaceuticals to launch a sponsored testing program, providing no-cost exome testing for eligible patients with unexplained cholestasis, early onset cataracts, or suspected or confirmed peroxisome biogenesis disorder–Zellweger spectrum disorder (PBD-ZSD).
•Partnered with Beren Therapeutics P.B.C. to launch the NPC GenomeComplete Sponsored Testing Program, providing no-cost comprehensive genome sequencing for eligible pediatric patients with clinical findings, family history, or biomarker evidence suggestive of Niemann-Pick Disease Type C (NPC).
Expanded Coverage for Exome and Genome
•Expanded the number of state Medicaid programs covering whole genome sequencing to 25 with the addition of Arkansas and Utah Medicaid.
•Appointed Nicole Maassen, J.D. as Chief Patient Access Officer to lead Market Access and Government Affairs with a focus
Aug 3, 2026 · 39% conf.
1D
+8.36%
$73.53
Act: +5.14%
5D
+18.74%
$80.58
Act: +14.77%
20D
+23.73%
$83.96
2 exhibit991-q22026pressrele.htm
Document
Exhibit 99.1
GeneDx Reports Second Quarter 2026 Financial Results
•Reported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue
•Reported exome and genome volume growth of 32% year-over-year
•Reported adjusted gross margin(1) of 70% and adjusted net income(1) of $0.4 million
•Reiterating full year 2026 revenue guidance of $475 to $490 million with exome and genome volume growth of at least 30%
•Hosting conference call today at 4:30 p.m. ET
GAITHERSBURG, Md., August 3, 2026 — GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the second quarter of 2026.
“Our team’s unwavering focus and agility drove a strong second quarter. By delivering healthy revenue, volume, and gross margin growth, we successfully navigated our return to profitability” said Katherine Stueland, CEO of GeneDx. “We are managing the transition to genome testing, making progress on each of our key imperatives — optimizing unit economics, growing utilization, and delivering the best products at unmatched scale — while continuing to extend our industry-leading position in both exome and genome testing to reach as many patients and families as soon as possible.”
Second Quarter 2026 Financial Results (Unaudited)(1)
Revenue
•Revenue grew to $114.4 million, an increase of 11% year-over-year.
•Exome and genome test revenue grew to $100.3 million, an increase of 17% year-over-year.
Exome and genome volume
•Exome and genome test result volume grew to 30,785, an increase of 32% year-over-year.
Gross margin
•Adjusted gross margin of 70% in the second quarter of 2026 is up from 69% in the first quarter of 2026 and compares to 71% in the second quarter of 2025.
◦GAAP gross margin was 68%.
Operating expenses
•Adjusted total operating expenses were $80.3 million, representing 70% of revenue.
◦Total GAAP operating expenses were $95.7 million.
Net income
•Adjusted net income was $0.4 million, up $8.6 million from the first quarter of 2026 and compared to adjusted net income of $16.4 million in the second quarter of 2025.
◦GAAP net loss was $17.7 million.
Cash position
•Cash, cash equivalents, marketable securities and restricted cash was $133.5 million as of June 30, 2026.
•On August 3, 2026, the Company amended and restated its existing loan agreement with Blackstone, adding an additional $50.0 million term loan facility and increasing the aggregate principal amount available under the facility to $150.0 million. Concurrently, an affiliate of Blackstone agreed to purchase approximately $5.0 million of the Company’s Class A common stock at $61.00 per share in a private placement.
◦Combined with the cash, cash equivalents, marketable securities and restricted cash balance of $133.5 million as of June 30, 2026, the Company’s pro forma cash position following this transaction is approximately $188 million.
(1)Adjusted gross margin, adjusted total operating expenses and adjusted net income are non-GAAP financial measures. See appendix for a reconciliation of GAAP to non-GAAP figures presented.
GeneDx 2026 Guidance
GeneDx has reaffirmed its full year 2026 guidance and has provided guidance for the third quarter of 2026. Management expects GeneDx to deliver:
MetricFull Year 2026 GuidanceThird Quarter 2026 Guidance
Revenue $475 to $490 million
$122 to $124 million
Exome and genome volume At least 30% growth
33,200 tests
Exome and genome revenue At least 20% growth
$110 to $112 million
Adjusted gross margin Approximately 70%
Approximately 70%
Adjusted net income Positive
Approximately $2 million
Second Quarter 2026 and Recent Business Highlights
Strategic Expansion and Market Leadership
•Appointed Mark Gardner as President to lead GeneDx’s commercial and operations teams through the next phase of growth, with a focus on strengthening execution, scaling efficiently, and expanding the company’s leadership in genomic medicine.
•Launched redesigned exome and genome reports to streamline the delivery of genomic insights to non-genetics clinicians as part of a broader suite of customer experience improvements rolling out this summer.
Expanded Coverage for Exome and Genome
•Improved access to exome sequencing in Texas with new Medicaid coverage effective May 1, 2026, building on existing genome sequencing coverage in the state.
•Received California Medicaid (Medi-Cal) pricing for genome sequencing effective July 1, 2026, with pricing published at 100% of the Medicare rate. Coverage for genome sequencing in California was originally announced as effective November 1, 2025.
•Secured outpatient genome sequencing coverage from Carelon, the nation’s largest lab benefit manager, opening access to up to 56 million covered lives. The policy is effective June 14, 2026.
•Expanded the total number of state Medi
May 4, 2026
2 exhibit991-q12026pressrele.htm
Document
Exhibit 99.1
GeneDx Reports First Quarter 2026 Financial Results and Updates Full-Year Outlook
•Reported first quarter 2026 revenue of $102.3 million with 27% year-over-year growth in exome and genome revenue
•Reported exome and genome volume growth of 34% year-over-year
•Reported adjusted gross margin(1) of 69% and adjusted net loss(1) of $8.2 million
•Updating full-year 2026 revenue guidance to $475 to $490 million with exome and genome volume growth of at least 30%
•Hosting conference call today at 4:30 p.m. ET
GAITHERSBURG, Md., May 4, 2026 — GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the first quarter of 2026.
“GeneDx delivered 34% year-over-year volume growth in exome and genome testing in the first quarter – a clear signal that there’s sustained, strong demand for our services. While our revenue did not reflect the full potential of what this business is capable of, we are adjusting our outlook and are poised to deliver more than 30% volume growth, 70% gross margin, and profitability on an adjusted basis for the year,” said Katherine Stueland, CEO of GeneDx. “Leading a generational shift in medicine requires taking some big swings, learning quickly, and moving with urgency to serve this ever-growing patient population. With expectations reset, we’ve never been more confident about our ability to deliver profitable growth in service of patients and shareholders.”
First Quarter 2026 Financial Results (Unaudited)(1)
Revenue
•Revenue grew to $102.3 million, an increase of 17% year-over-year.
•Exome and genome test revenue grew to $90.6 million, an increase of 27% year-over-year.
Exome and genome volume
•Exome and genome test result volume grew to 27,488, an increase of 34% year-over-year.
Gross margin
•Adjusted gross margin remained flat at 69% in the first quarter of 2026.
◦GAAP gross margin was 67%.
Operating expenses
•Adjusted total operating expenses were $78.1 million, representing 76% of revenue.
◦Total GAAP operating expenses were $94.4 million.
Net (loss) income
•Adjusted net loss was $8.2 million compared to adjusted net income of $9.2 million in the first quarter of 2025.
◦GAAP net loss was $63.3 million.
Cash position
•Cash, cash equivalents, marketable securities and restricted cash was $171.7 million as of March 31, 2026.
(1)Adjusted gross margin, adjusted total operating expenses and adjusted net (loss) income are non-GAAP financial measures. See appendix for a reconciliation of GAAP to non-GAAP figures presented.
Updated 2026 Guidance
GeneDx has updated its 2026 guidance. Management now expects GeneDx to deliver:
Metric Full Year 2026
Previous Guidance
Full Year 2026
Updated Guidance
Second Quarter of 2026 Guidance
Revenue $540 to $555 million
$475 to $490 million
$110 to $112 million
Growth in exome and genome volume
33% to 35%
At least 30%
Approximately 30,000 tests
Growth in exome and genome revenue
33% to 35%
At least 20%
Approximately $100 million
Adjusted gross margin At least 70%
Approximately 70%
Approximately 70%
Adjusted net income (loss)
Positive
Positive
Adj. net loss of approximately $5 million
First Quarter 2026 and Recent Business Highlights
Strategic Expansion and Market Leadership
•Announced the landmark SAVES-Kids study, a real-world data Health Economics and Outcomes Research (HEOR) analysis, showing an average healthcare cost savings of up to $80,000 for children with neurodevelopmental disorders in the 12 months following ExomeDx™ and GenomeDx™ testing, regardless of the test result.
•Launched a reflex product, enabling seamless reflexing to genome testing when exome testing is non-diagnostic.
•Partnered with CNBC to launch CNBC Cures, a collaborative, multi-platform initiative aimed at raising awareness for the rare disease community and improving outcomes for the ~30 million Americans affected by rare diseases.
•Launched a sponsored genetic testing program with Zevra Therapeutics to support patients with suspected Niemann-Pick Disease Type C.
•Expanded Medicaid coverage in Texas, Maine, and Arkansas, resulting in approximately 4.9 million Medicaid patients gaining access to exome testing.
Innovation & Clinical Leadership
•Added to the company’s more than 1,100 publications by showcasing 18 pieces of pioneering research at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting. The research highlighted the scale and clinical impact of GeneDx Infinity™ – the largest and most comprehensive rare disease genomic dataset – and GeneDx’s leadership in bringing exome and genome testing to the standard of care by leveraging AI, world-class data and clinical expertise, and expert variant interpretation and classification.
•Published results from a benchmarking study in the American Journal of Human Genetics demon
See how WGS stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "WGS GeneDx Holdings Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.